Dedicated to increasing the understanding of medical cannabis’ many benefits, Aleafia Labs deploys Big Data to influence patient care. Our mission, providing the most advanced doctor and patient support, will be data based, deriving from in-depth research and development strategies on the latest industry findings. This will provide further insight into cannabis’ many uses, ensuring appropriate and safe patient consumption. Using Canabo Medical Clinic’s vast historical data, Aleafia Labs' new clinical products will achieve the highest possible efficiency rates.
With extensive medical potential, Cannabinoids like THC and CBD, the key chemical components in cannabis, are extremely effective in treating many medical conditions and provide a wide range of symptom relief.
For example, medical cannabis can be used to treat both acute and chronic pain caused by arthritis and fibromyalgia. It helps reduce muscle spasms caused by multiple sclerosis, Tourette’s syndrome, and Parkinson’s. Medical cannabis has long been used as an appetite stimulant for cancer patients undergoing chemotherapy, and new research shows its promise in helping to treat PTSD, opioid addiction, sleep disorders, gastrointestinal diseases, and epilepsy.
While much medical cannabis research has been carried out, more is necessary. Aleafia Labs will partner with other cannabis scientists to advance important breakthroughs and determine how to better propagate the medical properties of cannabis plants. We look forward to discovering new ways to engineer strains that most effectively treat particular medical conditions, ensuring our patients are guided and monitored based on the most up-to-date research.
With medical cannabis research advancing globally, Aleafia Labs keeps the Aleafia brand at the forefront of innovation by studying cannabis’ effectiveness on opioid dependence, medical treatment and patient recovery. As new studies are conducted, Aleafia Health will evolve and adapt with the newest scientific discoveries.
Using a placebo-controlled crossover trial, 42 subjects inhaled 4 puffs of vaporized cannabis consisting of either a placebo, 2.9% THC, or 6.7% THC on 3 separate occasions. A significant analgesic effect was noted for vaporized cannabis, with psychoactive and subjective effects being dose-dependent. At this point, the lower dose appears to offer the best risk-to-benefit ratio; however, additional research is required to further evaluate the efficacy.
Wilsey, B., Marcotte, T. D., Deutsch, R., Zhao, H., Prasad, H., & Phan, A. (2016). An exploratory human laboratory experiment evaluating vaporized cannabis in the treatment of neuropathic pain from spinal cord injury and disease. The Journal of Pain, 17(9), 982-1000.Read Study
Non-cardiac chest pain is typically categorized as either gastroesophageal reflux disorder related to esophageal motility disorders or functional chest pain related to hypersensitivity. Only 40-50% of patients notice an improvement with current treatments. In this double-blind placebo controlled trial, participants received either dronabinol or a placebo twice a day for 4 weeks. Baseline testing included an esophageal balloon distention test, chest pain, general health, anxiety, and depression. After 4 weeks, no changes in anxiety and depression were noted, yet the pain threshold increased significantly, and a reduced pain intensity and decreased odynophagia were noted when compared to the placebo. Further studies are required to corroborate these findings.
Malik, Z., Bayman, L., Valestin, J., Rizvi-Toner, A., Hashmi, S., & Schey, R. (2017). Dronabinol increases pain threshold in patients with functional chest pain: a pilot double-blind placebo-controlled trial. Diseases of the esophagus: official journal of the International Society for Diseases of the Esophagus, 30(2), 1-8.Read Study
Using a randomized, double-blind, placebo-controlled crossover design, 16 patients with painful diabetic peripheral neuropathy were given 4 single doses of either a placebo or a low (1% THC), medium (4% THC), or high (7% THC) dose of THC. Pain intensity and subjective “highness” were measured at 5, 15, 30, 45, and 60 minutes, then every 30 minutes for the following 3 hours. Findings indicated a dose-dependent reduction in diabetic peripheral neuropathic pain.
Wallace, M. S., Marcotte, T. D., Umlauf, A., Gouaux, B., & Atkinson, J. H. (2015). Efficacy of inhaled cannabis on painful diabetic neuropathy. The Journal of Pain, 16(7), 616-627.Read Study
The lack of standard dosing presents a major obstacle in cannabis becoming a customary pharmacological treatment. In this study, pharmacokinetics, safety, tolerability, efficacy, and ease of use were explored using 8 participants in a single-dose, open-label study. A 15.1 +/- 0.1mg dose of cannabis in a Syqe Inhaler was administered to patients. A baseline pain scale and blood sample were taken and again at 120 minutes post-administrations. An identical pharmacokinetic profile was found across all patients, including a higher plasma Cmax per mg change in THC administration, as well as lower individual variability of Cmax when equated to alternative means of THC delivery. With only a mild lightheadedness requiring no intervention, a significant 45% reduction in pain intensity was found within 20 minutes post-inhalation and returning to baseline after 90 minutes.
Eisenberg, E., Ogintz, M., & Almog, S. (2014). The pharmacokinetics, efficacy, safety, and ease of use of a novel portable metered-dose cannabis inhaler in patients with chronic neuropathic pain: a phase 1a study. Journal of Pain & Palliative Care Pharmacotherapy, 28(3), 216-225.Read Study
This study looked at 10 patients with chronic PTSD on stable medication. The patients received 5mg of THC twice a day as an addition to their current medication regimen. Mild adverse effects were seen in 20% of patients, requiring no intervention. Significant improvement was noted in symptom severity, sleep quality, frequency of nightmares, and PTSD hyper-arousal.
Roitman, P., Mechoulam, R., Cooper-Kazaz, R., & Shalev, A. (2014). Preliminary, open-label, pilot study of add-on oral Δ 9-tetrahydrocannabinol in chronic post-traumatic stress disorder. Clinical Drug Investigation, 34(8), 587-591.Read Study
Participants in this double-blind experiment were Canadian male military personnel with PTSD who received standard treatments yet still experienced trauma-related nightmares. Participants were started on 0.5mg NAB or a placebo and titrated to a therapeutic dose that resulted in no nightmares. The experiment consisted of two 7-week periods with a 2-week washout in between. During the first 7 weeks, the participants received either NAB or the placebo, whereas in the second 7 weeks, they received the opposite. 50% reported significant improvement on NAB; however, only 11% reported improvements when given the placebo. Although 50% reported mild adverse effects on NAB, 60% reported mild adverse effects on the placebo. The results of this experiment indicate that NAB may provide significant relief of nightmares to those with chronic PTSD; however, further large-scale studies are required to validate these findings.
Jetly, R., Heber, A., Fraser, G., & Boisvert, D. (2015). The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology, 51, 585-588.Read Study
Anxiety is the most common mental health disorder among Canadians, yet only 40-60% of sufferers respond to treatment. Furthermore, current treatments for anxiety often come with significant adverse effects. The Canadian Network for Mood and Anxiety Treatment has developed criteria for establishing effective treatments. For example, only therapies that score a 1 or a 2 should be considered as first-line treatment options. Therapies that score a 3 or higher may be useful in conjunction with a level 1 or 2 therapy. Cannabinoids are considered a level 3 for social anxiety, generalized anxiety, PTSD, trichotillomania (hair pulling), and Tourette’s.
Turna, J., Patterson, B., & Ameringen, M. (2017). Is cannabis treatment for anxiety, mood, and related disorders ready for prime time? Depression and Anxiety.Read Study
Generalized social anxiety disorder (SAD) is the most common anxiety disorder. Cannabidiol (CBD) is a non-psychotomimetic cannabinoid. During a randomized double-blind experiment, 24 never-treated patients were divided into two groups. 12 were given CBD and the other 12 were given a placebo. An additional 12 patients were given no treatment. Using a visual analogue mood scale, a negative self-statement scale, as well as physiological measures (such as vital signs), the anxiety levels of participants were evaluated 6 different times throughout the experiment. CBD treatments prior to sessions greatly reduced anxiety, cognitive impairments, and discomfort in speech presentation whereas those treated with a placebo showed increased anxiety, cognitive impairment, and discomfort.
Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., De Oliveira, D. C. G., De Martinis, B. S., Kapczinski, F., ... & Martín-Santos, R. (2011). Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology, 36(6), 1219.Read Study
There have been multiple studies indicating CBD has anxiolytic properties; however, none have looked at the neurological functions related to anxiety. This experiment involved 10 patients diagnosed with SAD in a double-blind design. During the experiment, regional blood flow was measured using neuroimaging in two separate sessions. For the first session, the patient was given either CBD or a placebo, whereas for the second session, the patient was given the opposite. Results indicate that CBD reduces anxiety in SAD.
Crippa, J. A. S., Derenusson, G. N., Ferrari, T. B., Wichert-Ana, L., Duran, F. L., Martin-Santos, R., ... & Filho, A. S. (2011). Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. Journal of Psychopharmacology, 25(1), 121-130.Read Study